Inclusion Criteria:

• Participants with an endoscopically confirmed diagnosis of moderate to severe ulcerative colitis.
• Participants initiating risankizumab at the investigator's discretion as part of their routine clinical care; the decision to administer risankizumab must be made prior to and independent of documentation for the study and according to the approved local label.

Exclusion Criteria:

• Participants previously exposed risankizumab
• Participants who are currently participating in interventional research (not including noninterventional studies, post-marketing observational study (PMOS), or registry participation).